Showing 4111-4120 of 5771 results for "".
- Ocuphire Added to the Russell Microcap Indexhttps://modernod.com/news/ocuphire-added-to-the-russell-microcap-index/2479285/Ocuphire Pharma announced that the company is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021. Membership in th
- Iveric Bio to Host Investor Symposium on Dry AMDhttps://modernod.com/news/iveric-bio-to-host-investor-symposium-on-dry-amd/2479282/Iveric bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium for investors and analysts being held on Friday, June 18, 2021 from 10 am to 12 pm Eastern Time. The symposium will include presentations on the company’s Zimura (avacincaptad pegol) pivotal program in geo
- Glaukos Completes Patient Enrollment in US NDA Phase 3 Clinical Trials for iDose TRhttps://modernod.com/news/glaukos-completes-patient-enrollment-in-us-nda-phase-3-clinical-trials-for-idose-tr/2479280/Glaukos announced the completion of patient enrollment and randomization in its FDA new drug application (NDA) phase 3 clinical trials for the iDose TR sustained-release travoprost implant. The iDose TR phase 3 clinical program consists of two prospective, randomized, double-
- EyeYon Medical Receives CE Mark for its EndoArt Implant to Treat Chronic Corneal Edemahttps://modernod.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/2479277/EyeYon Medical announced that it has received CE Mark for its EndoArt after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. EyeYon says the EndoArt is the world’s first and only synthetic implant that replaces the human endothelium that the human
- J&J Vision Launches Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System in Europehttps://modernod.com/news/jj-vision-announces-launch-of-tecnis-eyhance-toric-ii-iol-with-tecnis-simplicity-delivery-system-in-europe/2479274/Johnson & Johnson Vision announced the launch and availability of its Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System for the treatment of cataracts patients with astigmatism in Europe. This monofocal lens allows for high-quality vision at both intermediate and far distance
- Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of Eyetelligence Clinical Decision Support Softwarehttps://modernod.com/news/bausch-lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software/2479271/Bausch + Lomb announced that its affiliate has entered into an agreement with Lochan LLC to develop the next-generation of Bausch + Lomb’s eyeTELLIGENCE clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed t
- Oxurion Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-completes-patient-enrollment-for-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-dme/2479273/Oxurion NV announced the completion of patient enrollment into Part A of its two part phase 2 study (KALAHARI) evaluating multiple injections of THR-149 for the treatment of DME. Dose selection data from Part A of the study is expected in the second half of 2021. THR-149, Oxurion’s most ad
- International Sports Vision Association and Macuhealth Offer New Educational Resource on Sports Nutrition for Your Eyeshttps://modernod.com/news/international-sports-vision-association-and-macuhealth-offer-new-educational-resource-on-sports-nutrition-for-your-eyes/2479270/The International Sports Vision Association (ISVA) and MacuHealth announced the launch of “Sports Nutrition for Your Eyes,” a new educational resource on the ISVA website designed to help educate athletes about how proper nutrition ca
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro